Enalapril Maleate Tablets USP, 5 mg, 100 Tablets (10X10) blister cards, 12 cartons in a shipper, ...
FDA Drug Recall #D-0915-2018 — Class III — June 25, 2018
Recall Summary
| Recall Number | D-0915-2018 |
| Classification | Class III — Low risk |
| Date Initiated | June 25, 2018 |
| Status | Terminated |
| Voluntary | — |
Recalling Firm
| Firm | AMERICAN HEALTH PACKAGING |
| Location | Columbus, OH |
| Product Type | Drugs |
| Quantity | 1285 cartons (cartons of 100 individual unit doses) |
Product Description
Enalapril Maleate Tablets USP, 5 mg, 100 Tablets (10X10) blister cards, 12 cartons in a shipper, Rx, Packaged and Distributed by: American Health Packaging, Columbus, OH --- NDC 68084-390-01 Carton [68084-390-11 - Unit Dose]
Reason for Recall
Failed Impurities/Degradation Specification; out-of-specification results for the Enalapril DKT degradant
Distribution Pattern
Lot#166023 products distributed from 12/29/16 to 1/19/17 and Lot#168467 distributed from 4/6/17 to 9/11/17. Distributors are the wholesalers who received the product; others are the Corporate Offices for those wholesalers.
Lot / Code Information
Lot# 166023 - Exp. 11/30/18 (232 units). Lot# 168467 - Exp. 2/28/19 (1053 units).
Other Recalls from AMERICAN HEALTH PACKAGING
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0880-2022 | Class III | Nitrofurantoin Capsules, USP (Monohydrate/Macro... | May 3, 2022 |
| D-0790-2022 | Class III | Cyanocobalamin Injection, USP, 1000 mcg per mL,... | Apr 12, 2022 |
| D-0652-2022 | Class II | Oxycodone Hydrochloride Oral Solution, USP (C-I... | Feb 22, 2022 |
| D-0451-2022 | Class II | Metoprolol Succinate Extended-Release Tablets, ... | Dec 20, 2021 |
| D-0020-2022 | Class II | GlipiZIDE Extended-Release Tablets, 2.5 mg, 30 ... | Sep 17, 2021 |
Frequently Asked Questions
Nitrosamines are probable human carcinogens — they can increase cancer risk with long-term exposure above certain thresholds, but they do not cause immediate harm from taking a single dose. The FDA calculates an acceptable daily intake (ADI) for each nitrosamine compound, and recalls are triggered when levels exceed this threshold. If you have been taking a recalled product, the FDA generally advises against abruptly stopping your medication (especially for critical conditions like blood pressure or diabetes) until you consult your doctor. The incremental cancer risk from short-term exposure is very small.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.